Startup profile for IntelliProve: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

IntelliProve funding, valuation and investors

Computer-vision-based physiological estimates from ordinary cameras for digital health platforms.

Verified company research · funding, investors and latest developments

Keep track of IntelliProve

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Seed

€2.7M · November 19, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

seed · Ghent, Belgium

Investors in latest funding

Lead: Miles Ahead

Other: Wit-Gele Kruis , imec.istart

Sources: latest funding · eu-startups.com Last verified: 2026-11-20

Overview

Ghent company founded in 2021. Provides remote-photoplethysmography (rPPG) face-scan SDK and web components for camera-based heart rate, heart-rate variability, respiratory rate, estimated blood pressure and related wellness measures. November 19, 2026 press reports describe a €2.7M Seed led by Miles Ahead with Wit-Gele Kruis, imec.istart and angels participating, with exact closing date and valuation undisclosed.

Its own January 20, 2025 release documented a separate €1.25M investment. Developer docs specify roughly 20 seconds scanning while recent press descriptions say 30 seconds. Software-integration workflow: issue session token, request camera access, verify lighting and head positioning, run face scan, present biomarker widgets and escalate clinically important readings for conventional verification. Enterprise pricing is quote-based.

Do not interpret vendor-reported adoption in 50+ countries or an intended robotics use case as medical approval or evidence of diagnostic accuracy. Earlier 2025 company marketing describes CE status while a 2026 company job listing refers to a device still heading for CE marking; exact device/version and indication need verification.

Why IntelliProve is interesting

A reported €2.7M Seed led by Miles Ahead funds clinical validation and potential robotics integrations. The critical question is blood-pressure and heart-rate measurement reliability outside controlled settings, not the fundraising itself.

Product & use cases

B2B SDK rather than a dedicated physical scanner. Illustrative first visit: clinician/wellbeing platform obtains API token, embeds ip-session and face-scan widget, user grants camera, quality checks light/position, software returns physiological estimates, app shows relevant metrics and retains human escalation for clinical concerns. Source: https://docs.intelliprove.com/product-docs/face-scan-plug-in. No independently validated error rates or list price were established.

  • Remote-care platform adds a contactless screening interaction.
  • Wellness application displays an indicative physiological snapshot from a camera.
  • Robotics developer could test health sensing on a moving camera; not a confirmed deployed medical application.

Funding history (newest first)

Seed

2026-11-19 €2.7M
  • Miles Ahead (lead)
  • Wit-Gele Kruis (participant)
  • imec.istart (participant)

Source: Read source · eu-startups.com

Earlier financing (series undisclosed)

2025-01-20 €1.25M

Source: Read source · intelliprove.com

Competitive landscape

Edge: No specialized sensor required, but device compatibility, lighting bias, clinical accuracy and regulatory scope must be independently tested.

  • Binah.ai direct

    Camera-based vital-sign estimation SDK.

  • NuraLogix direct

    Contactless optical health measurements.

  • Traditional blood-pressure cuff alternative

    Validated direct measurement for clinical workflows.

  • Wearable PPG devices alternative

    Continuous measurements using dedicated hardware.

Notable stories

  • Technology availability is not the same as medically validated accuracy; recent robotics use is a plan.
  • Current documentation shows 20-second face scan; recent funding reporting says 30 seconds.

Market / IPO context

Editorial / static context — not a live quote.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.